Oxford BioDynamics has signed an exclusive licence agreement with Nova Satra Diagnostics Asia (NSDA) to supply its products and reagents for the potential use in a non-invasive blood test.
The company is a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry.
NSDA is a Singaporean company that develops and commercialises blood-based diagnostic tests to provide the early detection of cancer.
The test
The tests will assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.
Specifically for Malaysia, Oxford BioDynamics has given consent for NSDA to grant an exclusive sub-licence to Genting Laboratory Services (Genting Berhad) to provide the breast cancer test.
Kane Black, Chief Executive Officer of NSDA, said:
“Breast cancer is the most prevalent cancer in females in Asia and early detection is an important factor in improving treatment outcomes and survival rates.”
Licence
Under the terms of the agreement, the licence grants NSDA the exclusive right to use Oxford BioDynamics’ products and reagents, for breast cancer patients.
NSDA will be solely responsible for completing the regulatory approval process and commercialisation activities of the breast cancer test within 13 territories in Asia.
EpiSwitch
The products and reagents will be provided through the Oxford BioDynamics EpiSwitch technology platform.
Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:
“Our EpiSwitch technology will be instrumental in the development of this novel blood-based test that will assist in the diagnosis of breast cancer in the Asian population.”
Kong Han Tan, President and Chief Operating Officer of Genting Berhad, added:
“We welcome the opportunity to work with Oxford BioDynamics for the transfer of their technology to our labs in Malaysia to enable us deliver a non-invasive blood test to assist in the diagnosis of breast cancer.”
